Pfizer's fourth-quarter results were negatively impacted by the strong U.S. dollar, but they were largely in-line outside of that. These ETFs may benefit if Pfizer shares continue to rise.
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
Pfizer will showcase third-quarter results, but investors will be more focused on the potential for its Inflectra drug, as well as its outlook on M&A.
Your retirement portfolio could get a salutary boost from biotech stocks along with ETFs in the sector that have generated large returns in 2016, producing double digit-gains.